Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib
June 11, 2021 09:00 ET
|
Constellation Pharmaceuticals , Inc.
Translational data support the disease-modifying potential of pelabresibCentral pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib...
Constellation Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference
May 31, 2021 09:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 31, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces First-Quarter 2021 Financial Results and Provides Business Update
May 10, 2021 07:00 ET
|
Constellation Pharmaceuticals , Inc.
Dosing underway in the Phase 3 MANIFEST-2 clinical trialRecommended Phase 2 dose determined for CPI-0209 and first patient dosed in the Phase 2 expansion cohortsUpcoming data presentation at ASCO...
Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2021 Results
April 27, 2021 11:30 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel...
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial Results
February 24, 2021 07:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
February 19, 2021 16:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 Results
February 18, 2021 10:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer
January 07, 2021 09:30 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief...
Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
January 06, 2021 10:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Jigar Raythatha, CEO, will present a company overview at the J.P....
Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting
December 06, 2020 08:00 ET
|
Constellation Pharmaceuticals , Inc.
67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeksCPI-0610 demonstrated activity, both as a monotherapy and as add on to...